SG Americas Securities LLC grew its holdings in Maximus Inc. (NYSE:MMS) by 20.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 23,081 shares of the health services provider’s stock after acquiring an additional 3,869 shares during the quarter. SG Americas Securities LLC’s holdings in Maximus were worth $1,540,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Maximus by 1.6% in the 4th quarter. BlackRock Inc. now owns 6,674,541 shares of the health services provider’s stock valued at $477,763,000 after acquiring an additional 107,376 shares during the last quarter. Brown Advisory Inc. increased its holdings in shares of Maximus by 0.8% in the 4th quarter. Brown Advisory Inc. now owns 1,187,070 shares of the health services provider’s stock valued at $84,973,000 after acquiring an additional 9,106 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its holdings in shares of Maximus by 6.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 741,734 shares of the health services provider’s stock valued at $53,093,000 after acquiring an additional 48,128 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Maximus by 5.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 726,384 shares of the health services provider’s stock valued at $51,995,000 after acquiring an additional 36,570 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Maximus by 10.6% in the 4th quarter. Geode Capital Management LLC now owns 641,629 shares of the health services provider’s stock valued at $45,927,000 after acquiring an additional 61,311 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.
In related news, CEO Richard A. Montoni sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $67.89, for a total transaction of $2,036,700.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Russell A. Beliveau sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $66.55, for a total value of $66,550.00. The disclosure for this sale can be found here. Insiders have sold a total of 41,000 shares of company stock worth $2,777,450 in the last 90 days. 3.10% of the stock is currently owned by company insiders.
Maximus opened at $62.24 on Friday, Marketbeat Ratings reports. The company has a market cap of $4.04 billion, a P/E ratio of 20.54, a PEG ratio of 2.39 and a beta of 1.13. Maximus Inc. has a 52-week low of $58.58 and a 52-week high of $72.71.
Maximus (NYSE:MMS) last released its quarterly earnings results on Thursday, May 10th. The health services provider reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.02). The firm had revenue of $612.79 million for the quarter, compared to analysts’ expectations of $617.97 million. Maximus had a return on equity of 21.67% and a net margin of 9.15%. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 EPS. analysts expect that Maximus Inc. will post 3.24 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, May 31st. Investors of record on Tuesday, May 15th will be paid a dividend of $0.045 per share. The ex-dividend date of this dividend is Monday, May 14th. This represents a $0.18 dividend on an annualized basis and a yield of 0.29%. Maximus’s dividend payout ratio is presently 5.94%.
A number of research firms have recently commented on MMS. First Analysis upgraded Maximus from an “equal” rating to a “weight” rating and increased their price objective for the company from $73.00 to $81.00 in a report on Tuesday, May 8th. Maxim Group reiterated a “hold” rating and issued a $69.00 price objective (up previously from $66.00) on shares of Maximus in a report on Thursday, February 8th. Zacks Investment Research downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Canaccord Genuity dropped their price target on Maximus from $71.00 to $65.00 and set a “hold” rating on the stock in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $71.00.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.